Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sipavibart
- Development stage
- Phase 3
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intramuscular, Intravenous
01
Overview
Sipavibart (formerly AZD3152) is a long-acting monoclonal antibody (LAAB) developed by AstraZeneca for the pre-exposure prophylaxis of COVID-19 in immunocompromised individuals. It is a recombinant human IgG1-based antibody designed to provide broad and potent neutralization across various SARS-CoV-2 variants, including Omicron and ancestral strains. By binding to the SARS-CoV-2 spike protein, sipavibart prevents the virus from interacting with the host cell receptor ACE2, thereby blocking viral entry. The drug has received regulatory approval in Japan, the European Union, and Canada for use in adults and adolescents aged 12 and older who are immunocompromised and unlikely to mount an adequate immune response to vaccination.
- Brand names
- Kavigale
- Other names
- sipavibart
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on sipavibart.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sipavibart.